This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Identive Technologies, AMR:Small-Cap Winners

NEW YORK ( TheStreet) -- Shares of small-caps were under pressure on Monday amid broad market weakness. Still, a handful of stocks still managed to garner investor interest.

Identive Technologies (INVE - Get Report), which operates in the radio frequency identification systems (RFID) space, saw its shares more than double to $5.72.

ACiG Technology, a supplier and distributor of RFID products and a business unit of Identive Group announced that is has been selected as the exclusive supplier of near field communication RFID stickers for the roll out of Google's marketing campaign for Google Places in Austin, Texas. The NFC stickers are manufactured by ACiG's sister company, Smartag. Over 12 million shares changed hands by Monday afternoon.

Shares of nursing home operator Skilled Healthcare (SKH) were climbing 8% to $15.16 after it said late Monday that it was exploring strategic alternatives, including putting itself up for sale.

AVI Pharma (AVII) was another stock gaining in the biotech space, rising 4.3% to $1.68 after Piper Jaffray initiated coverage on the stock with an overweight rating and a $3.50 price target on the stock.

Airline stocks were gaining on Monday on the back of a retreat in crude oil prices. Shares of AMR (AMR), parent of American Airlines, was up 2.7% to $5.92. US Airways (LCC) saw its stock add 3.7% to $8.54. Shares of JetBlue Airways (JBLU - Get Report) was ahead by 2%.

Exelixis (EXEL - Get Report) was a standout performer in the pharmaceutical space, climbing 2.5% to $11.37. According to a Bloomberg news report, the company is said to be hiring Goldman Sachs to prepare for potential takeovers after its experimental prostate cancer drug performed well in a study.

-- Written by Shanthi Bharatwaj in New York



>To contact the writer of this article, click here: Shanthi Bharatwaj.

>To follow the writer on Twitter, go to http://twitter.com/shavenk.

>To submit a news tip, send an email to: tips@thestreet.com.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
LCC $0.00 0.00%
SKH $8.44 4.46%
EXEL $2.93 0.00%
INVE $9.67 0.00%
JBLU $17.19 0.00%

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs